UTMD
Strong BuyFull HouseAPPROVEUtah Medical Products, Inc. · Healthcare · United States · $232M · Avg Vol: $3M/d
Full House: Strong business, sensible price, market agrees. The rare full house.
Utah Medical Products makes niche obstetrics and neonatal devices with unusually high and stable operating margins, no meaningful debt and a long unbroken dividend record, which supports the quality score and firm momentum. Nothing adverse is known on accounting, solvency or governance. Durable margins plus a fortress balance sheet clear the screen comfortably.
ABOUT UTAH MEDICAL PRODUCTS, INC.
Read
Utah Medical Products, Inc. designs, manufactures, and markets a diverse portfolio of disposable and reusable medical devices for niche healthcare markets, including obstetrics, neonatology, urology, and gynecology. Its competitive moat is built on proprietary product designs, vertically integrated manufacturing capabilities, and a focus on high-quality, specialized solutions that address specific clinical needs. UTMD operates as a lean, focused medical device innovator serving critical patient care areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 52.3M | 50.2M | 40.9M | 38.5M | -9.7% | 36.1M |
| EPS | 5.69 | 4.58 | 4.16 | 3.54 | -14.6% | 3.28 |
| Shares | 3.6M | 3.6M | 3.3M | 3.2M | -12.2% | 3.2M |
| Debt | 0.3M | 0.3M | 0.3M | 0.2M | -12.9% | 0.2M |
| Equity | 114.3M | 128.3M | 117.4M | 119.3M | 1.4% | — |
| Op CF | 21.1M | 22.3M | 14.8M | 14.7M | -11.4% | 11.8M |
| Inv CF | -0.8M | -0.6M | -0.2M | -0.4M | — | — |
| Fin CF | -5.5M | -4.2M | -23.8M | -12.3M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of UTMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| UTMD | Utah Medical Products, Inc.(you) | $232M | 94 | Strong Buy |
| PDEX | Pro-Dex, Inc. | $200M | 95 | Strong Buy |
| EMBC | Embecta Corp. | $286M | 88 | Strong Buy |
| SMTI | Sanara MedTech Inc. | $318M | 68 | Buy |
| OSUR | OraSure Technologies, Inc. | $248M | 33 | Sell |
| ANGO | AngioDynamics, Inc. | $655M | 52 | Hold |
| NVST | Envista Holdings Corporation | $4.4B | 85 | Strong Buy |
| STAA | STAAR Surgical Company | $1.1B | 57 | Hold |
| DXR | Daxor Corporation | $60M | 50 | Hold |
| MMSI | Merit Medical Systems, Inc. | $5.4B | 82 | Strong Buy |
Peer medians: ROE -31.0% · P/E 25.2x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.